RECRUITINGOBSERVATIONAL
The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.
A Prospective Observational Study on the Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.
About This Trial
This study aims to assess the level of participation of thoracic cancer patients undergoing definitive radiotherapy and chemotherapy ± immunotherapy in their medical processes and the association between the level of participation and patients' side effects, quality of life, and long-term survival. Additionally, this study will rate the level of participation from both the patients' and medical staff's perspectives and will compare the differences in ratings from these two viewpoints, as well as their impact on treatment outcomes.
Who May Be Eligible (Plain English)
Who May Qualify:
- Locally advanced non-small cell lung cancer, limited-stage small cell lung cancer, and esophageal cancer.
- Planned to undergo definitive chemoradiotherapy ± immunotherapy;
- Males or females aged 18 to 75;
- Able to communicate with medical staff.
Who Should NOT Join This Trial: Patients with cognitive impairments.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Locally advanced non-small cell lung cancer, limited-stage small cell lung cancer, and esophageal cancer.
* Planned to undergo definitive chemoradiotherapy ± immunotherapy;
* Males or females aged 18 to 75;
* Able to communicate with medical staff.
Exclusion Criteria: Patients with cognitive impairments.
Locations (1)
Sun Yat-sen University
Guangzhou, China